Bicycle therapeutics announces significant progress across multiple therapeutic programs beyond oncology

Cambridge, england & boston--(business wire)--bicycle therapeutics plc (nasdaq: bcyc), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (bicycle®) technology, today announced progress updates for its bicycle-based partnered programs outside of oncology. “over the last five years, bicycle's strategy has been to use our novel technology to discover and develop a pipeline of innovative assets in oncology while additionally
BCYC Ratings Summary
BCYC Quant Ranking